为晚期泌尿生殖系统癌症患者开发肿瘤浸润淋巴细胞疗法的机遇与障碍。

The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.

作者信息

Potez Marine, Roman Souza Gabriel, Spiess Philippe E, Pilon-Thomas Shari, Chahoud Jad

机构信息

Immuno-Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Genitourinary Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

出版信息

Nat Rev Urol. 2025 Sep 26. doi: 10.1038/s41585-025-01088-6.

DOI:10.1038/s41585-025-01088-6

PMID:41006825

Abstract

Adoptive cell therapy using tumour-infiltrating lymphocytes (TILs) has been a very successful model of enhancing immune-based therapies. Clinical benefits have been shown for patients with advanced melanoma, leading to the first FDA approval for this immune modality in 2024. Although clinical trials conducted decades ago for advanced renal-cell cancer did not show significant clinical benefits, recent advances in the TIL generation process, manipulation techniques, preparative regimens and combination with immune checkpoint inhibitors offer new hope for reexploring optimized TIL therapy for genitourinary cancers. The current landscape of TIL therapy has seen progress in TIL manufacturing, optimization and delivery methodologies that have the potential to improve the safety and efficacy of TIL therapy in the management of advanced genitourinary malignancies. Furthermore, innovative combination approaches and novel strategies could enhance the clinical viability of TIL therapy and warrant evaluation in clinical trials treating patients with genitourinary cancers.

摘要

使用肿瘤浸润淋巴细胞（TILs）的过继性细胞疗法是增强免疫疗法的一个非常成功的范例。晚期黑色素瘤患者已显示出临床获益，这使得该免疫疗法在2024年首次获得美国食品药品监督管理局（FDA）批准。尽管几十年前针对晚期肾细胞癌进行的临床试验未显示出显著的临床获益，但TIL生成过程、操作技术、预处理方案以及与免疫检查点抑制剂联合使用方面的最新进展为重新探索针对泌尿生殖系统癌症的优化TIL疗法带来了新希望。TIL疗法的当前发展态势在TIL制造、优化和递送方法方面取得了进展，这些进展有可能提高TIL疗法在晚期泌尿生殖系统恶性肿瘤治疗中的安全性和有效性。此外，创新的联合方法和新策略可以提高TIL疗法的临床可行性，并值得在治疗泌尿生殖系统癌症患者的临床试验中进行评估。